REFERENCES
1. Jubber I, Ong S, Bukavina L, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84:176-90.
2. Vermeulen R, Bodinier B, Dagnino S, et al. A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer. Eur J Epidemiol. 2024;39:393-407.
3. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8:15.
4. Massari F, Santoni M, Ciccarese C, et al. Emerging concepts on drug resistance in bladder cancer: implications for future strategies. Crit Rev Oncol Hematol. 2015;96:81-90.
5. Yue P, Han B, Zhao Y. Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches. Mol Omics. 2023;19:297-307.
6. Mari A, D’Andrea D, Abufaraj M, Foerster B, Kimura S, Shariat SF. Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. Transl Androl Urol. 2017;6:1081-9.
7. Khan SU, Fatima K, Aisha S, Malik F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal. 2024;22:109.
8. Earl J, Rico D, Carrillo-de-Santa-Pau E, et al. The UBC-40 urothelial bladder cancer cell line index: a genomic resource for functional studies. BMC Genomics. 2015;16:403.
9. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955-61.
10. Michaelis M, Wass MN, Cinatl J. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist. 2019;2:447-56.
11. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990;82:1107-12.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-9.
13. Pan H, Jansson KH, Beshiri ML, et al. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget. 2017;8:77181-94.
14. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Updat. 2017;32:23-46.
16. Nicholson LJ, Smith PR, Hiller L, et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 2009;125:1454-63.
17. Yeon A, You S, Kim M, et al. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism. Theranostics. 2018;8:4520-34.
18. Petruzzelli R, Polishchuk RS. Activity and trafficking of copper-transporting ATPases in tumor development and defense against platinum-based drugs. Cells. 2019;8:1080.
19. Saiki Y, Yoshino Y, Fujimura H, et al. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun. 2012;421:98-104.
20. Asai S, Miura N, Sawada Y, et al. Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells. Oncol Lett. 2018;15:522-7.
21. Xi Y, Yuan P, Li T, Zhang M, Liu MF, Li B. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 2020;479:112-22.
22. Saga Y, Hashimoto H, Yachiku S, Iwata T, Tokumitsu M. Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol. 2004;11:407-15.
24. Kavallaris M, Tait AS, Norris MD, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001;61:5803-9.
25. Liu Y, Kwiatkowski DJ. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther. 2015;14:174-82.
26. Zeng SX, Zhu Y, Ma AH, et al. The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer. Clin Cancer Res. 2017;23:6580-91.
27. Borcoman E, De La Rochere P, Richer W, et al. Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. Oncoimmunology. 2019;8:e1581556.
28. Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007;98:1303-10.
29. Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.
30. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001;7:2168-81.
31. Wei J, Zhao J, Long M, et al. p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC Cancer. 2010;10:632.
32. Martinez A, Hernandez A, Arpi O, et al. Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: rational for its testing in clinical trials. J Clin Oncol. 2015;33:369.
33. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869-83.
34. Chen HH, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs. 2010;2010:1-7.
35. Shi Y, Zheng H, Wang T, et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol Cancer. 2025;24:9.
36. Rapozzi V, Comuzzi C, Di Giorgio E, Xodo LE. KRAS and NRF2 drive metabolic reprogramming in pancreatic cancer cells: the influence of oxidative and nitrosatice stress. Front Cell Dev Biol. 2025;13:1547582.
37. Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer. 2021;2:271-83.
38. Mezencev R, Matyunina LV, Wagner GT, McDonald JF. Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther. 2016;23:446-53.
39. Arnesano F, Natile G. “Platinum on the road”: interactions of antitumoral cisplatin with proteins. Pure Appl Chem. 2008;80:2715-25.
40. Zheng J, Zhang W, Li L, et al. Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review. Front Chem. 2022;10:860985.
41. Lau DK, Jenkins L, Weickhardt A. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy. Cancer Drug Resist. 2019;2:568-79.
42. Li P, Wang D, Lu W, et al. Targeting FGFR3 signaling and drug repurposing for the treatment of SLC26A2-related chondrodysplasia in mouse model. J Orthop Translat. 2024;44:88-101.
43. Attaoua C, Vincent LA, Abdel Jaoued A, et al. Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids. Fundam Clin Pharmacol. 2015;29:62-71.
44. Pettitt GA, Hurst CD, Khan Z, et al. Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro. J Pathol. 2023;259:220-32.
45. Le TVT, Seo Y, Ryu CJ, Lee HR, Park HJ. Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Arch Pharm Res. 2010;33:1127-32.
46. Nickerson ML, Witte N, Im KM, et al. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene. 2017;36:35-46.
47. Koster R, di Pietro A, Timmer-Bosscha H, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120:3594-605.
48. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-22.
49. Cell. 2017;171:540-56.e25. Robertson AG, Kim J, Al-Ahmadie H, et al; TCGA Research Network. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540-56.e25.
50. Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004;10:4661-9.
51. Li ZH, Zheng R, Chen JT, Jia J, Qiu M. The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC). J Cancer. 2016;7:2085-92.
52. Li YQ, Yin JY, Liu ZQ, Li XP. Copper efflux transporters ATP7A and ATP7B: novel biomarkers for platinum drug resistance and targets for therapy. IUBMB Life. 2018;70:183-91.
53. Mangelinck A, da Costa MEM, Stefanovska B, et al. MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma. Sci Rep. 2019;9:12301.
54. Krause W. Resistance to anti-tubulin agents: from vinca alkaloids to epothilones. Cancer Drug Resist. 2019;2:82-106.
55. Seremak JR, Gupta KB, Bonigala S, et al. Targeting chemoresistance in advanced bladder cancers with a novel adjuvant strategy. Mol Cancer Ther. 2024;23:1389-403.
